Trials / Not Yet Recruiting
Not Yet RecruitingNCT06613373
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, exploratory clinical study
Detailed description
This is a single-arm, open-label, exploratory clinical study initiated by the investigator to evaluate the objective response rate (ORR), efficacy, and safety of Dalpiciclib combined with AI in the neoadjuvant treatment of stage Ⅱ-Ⅲ HR+/HER2- breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalpiciclib | Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle. |
Timeline
- Start date
- 2024-10-15
- Primary completion
- 2025-10-30
- Completion
- 2026-10-30
- First posted
- 2024-09-25
- Last updated
- 2024-09-25
Source: ClinicalTrials.gov record NCT06613373. Inclusion in this directory is not an endorsement.